GV1001 Subcutaneous(SC) for the Treatment of Moderate Alzheimer's Disease (AD)

NCT03959553 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped The study was stopped due to protocol amendment and project name change.

Conditions

Moderate Alzheimer's Disease

Interventions

DRUG: GV1001
DRUG: Normal saline

Sponsor

GemVax & Kael